Quantum Biopharma Ltd. (NASDAQ:QNTM) Short Interest Update

Quantum Biopharma Ltd. (NASDAQ:QNTM) was the target of a significant growth in short interest in January. As of January 30th, there was short interest totaling 76,665 shares, a growth of 63.2% from the January 15th total of 46,986 shares. Based on an average daily volume of 65,698 shares, the short-interest ratio is presently 1.2 days. Approximately 2.2% of the shares of the company are sold short. Approximately 2.2% of the shares of the company are sold short. Based on an average daily volume of 65,698 shares, the short-interest ratio is presently 1.2 days.

Institutional Trading of Quantum Biopharma

An institutional investor recently bought a new position in Quantum Biopharma stock. Steward Partners Investment Advisory LLC purchased a new position in shares of Quantum Biopharma Ltd. (NASDAQ:QNTM) during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 3,100 shares of the company’s stock, valued at approximately $63,000. Steward Partners Investment Advisory LLC owned 0.11% of Quantum Biopharma as of its most recent SEC filing. Institutional investors own 1.24% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Quantum Biopharma in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Quantum Biopharma from a “hold” rating to a “sell” rating in a research report on Saturday, January 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Quantum Biopharma currently has a consensus rating of “Sell”.

Quantum Biopharma Trading Down 0.3%

NASDAQ:QNTM opened at $3.64 on Monday. Quantum Biopharma has a 12-month low of $3.62 and a 12-month high of $38.25. The stock’s 50 day simple moving average is $6.88 and its 200-day simple moving average is $12.26. The firm has a market cap of $13.90 million, a P/E ratio of -0.33 and a beta of 0.30.

Quantum Biopharma Company Profile

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property.